WCAMG
NBRV

Woodard & Company Asset Management Group’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Woodard & Company Asset Management Group’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-80
Closed -$40K – 79
2019
Q3 		$40K Buy
+80
New +$45.1K 0.03% 62

Other funds holding NBRV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Woodard & Company Asset Management Group's NBRV Position: Q4 2019 in Review

Woodard & Company Asset Management Group sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q4 2019, closing a stake of 80 shares — an estimated $40K sold.

Woodard & Company Asset Management Group first reported a position in NBRV in Q3 2019 and held it in 1 quarter. The position peaked at $40K in Q3 2019. 50 funds tracked by Wall St. Rank hold NBRV as of Q4 2019.

  • Woodard & Company Asset Management Group reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q4 2019 after selling out during the quarter.
  • Woodard & Company Asset Management Group sold 80 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q4 2019, an estimated $40K.
  • Woodard & Company Asset Management Group first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q3 2019 and held it in 1 quarter.
  • Woodard & Company Asset Management Group's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $40K in Q3 2019.
  • 50 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q4 2019.

Based on Woodard & Company Asset Management Group's 13F filing for Q4 2019, filed 24 Jan 2020.